Skip to content

Clinical Observation on Yiqi Huoxue Formula Combined with Atorvastatin Calcium Tablets in Treating Elderly Dyslipidemia of Qi Deficiency and Blood Stasis Pattern

Clinical Observation on Yiqi Huoxue Formula Combined with Atorvastatin Calcium Tablets in Treating Elderly Dyslipidemia of Qi Deficiency and Blood Stasis Pattern

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001054
Enrollment
Unknown
Registered
2026-04-24
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia in the Elderly

Interventions

Experimental Group:Atorvastatin Calcium Tablets
Control Group:Atorvastatin Calcium Tablets + Yiqi Huoxue Formula

Sponsors

The Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Aged =60 and 3.4 mmol/L but <4.9 mmol/L); 3) Meet the TCM diagnostic criteria for dyslipidemia differentiated as Qi deficiency and blood stasis pattern; 4) No use of lipid-lowering agents, or have discontinued such medications for at least 2 weeks; 5) Liver function (AST, ALT) and renal function (Cr, UA) within normal ranges; 6) Willing to sign informed consent and able to actively participate.

Exclusion criteria

Exclusion criteria: 1) Dyslipidemia secondary to medications (e.g., antipsychotics, immunosuppressants, glucocorticoids, etc.); 2) TG =5.65 mmol/L, with risk of inducing serious complications such as acute pancreatitis, or when statin monotherapy fails to achieve effective lipid-lowering effects; 3) Hyperlipidemia secondary to other diseases such as nephrotic syndrome, hypothyroidism, or gout; 4) Dyslipidemia caused by adverse drug reactions, e.g., use of phenothiazines, heparin, or other medications that affect lipid metabolism; 5) Complicated by other severe conditions (e.g., acute exacerbation of severe cerebrovascular disease, cardiopulmonary system disease, or hematologic system disease); 6) Allergic constitution or a history of allergic reactions to the study medications; 7) Incomplete data provision or other factors that may interfere with the assessment.

Design outcomes

Primary

MeasureTime frame
Low-Density Lipoprotein Cholesterol (LDL-C);

Secondary

MeasureTime frame
Total Cholesterol(TC);Triglyceride(TG);High-Density Lipoprotein Cholesterol(HDL-C);

Countries

China

Contacts

Public ContactYang Xiaoping

The Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

yangxiaoping126@126.com13788905396

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026